



HBeAg-Negative
PegINF alfa-2a versus Lamivudine versus Both

PegINF alfa-2a versus Lamivudine versus Both HBeAg-Negative Patients: Study Design



PegINF alfa-2a versus Lamivudine versus Both HBeAg-Negative Patients: Results

HBeAg-NEGATIVE Patients: Week 72 Treatment Response



PegINF alfa-2a versus Lamivudine versus Both HBeAg-Negative Patients: Conclusions

Conclusions: “Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine. The addition of lamivudine to peginterferon alfa-2a did not improve post-therapy response rates.”